All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABC008
Therapeutic Area: Immunology Product Name: ABC008
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Mass General Brigham Ventures
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021
Details:
Proceeds from this financing will be used to advance ABC008, an anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy tissue in a variety of autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CDX-0159
Therapeutic Area: Immunology Product Name: CDX-0159
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
The Phase 1b study is an open label clinical trial designed to evaluate the safety of a single dose of CDX-0159, a humanized monoclonal antibody and KIT receptor inhibitor, in up to 20 patients with cold contact urticaria who are refractory to antihistamines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACE-1334
Therapeutic Area: Immunology Product Name: ACE-1334
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Acceleron plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATA188
Therapeutic Area: Immunology Product Name: ATA188
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Details:
Throughout the entire Phase 1a and OLE study, nine of the 16 patients who entered the OLE demonstrated sustained disability improvement (SDI) with ATA188 treatment (seven achieved SDI in the first twelve months and two during the OLE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: MyMD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020
Details:
Following the merger, the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets, including MYMD-1, a novel drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MGTA-145,Plerixafor
Therapeutic Area: Immunology Product Name: MGTA-145
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Magenta is developing MGTA-145 to be the first-line therapy for same-day mobilization and collection of hematopoietic stem cells (HSCs) for transplant, to enable successful rebuilding of the blood and immune system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Itolizumab
Therapeutic Area: Immunology Product Name: EQ001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Biocon Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Data will be presented demonstrating that modulation of the CD6-ALCAM pathway with itolizumab improves kidney and skin pathology in mouse models of SLE.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX-914
Therapeutic Area: Immunology Product Name: ADX-914
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed Advisors
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 29, 2020
Details:
Proceeds from the Series B financing will support the advancement of ADX-914 through demonstration of proof-of-mechanism and propel the company’s groundbreaking tissue-targeted complement regulation platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: TFFTAC-LAC
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicab
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
